Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

futuximab/modotuximab (S95026)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Servier

Drug class:

EGFR inhibitor

Related drugs:

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

zorifertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

asandeutertinib (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

›

RAS wild-type + BRAF wild-type	Colorectal Cancer	RAS wild-type + BRAF wild-type	Colorectal Cancer	S95026 Sensitive: C3 – Early Trials S95026 Sensitive : C3	S95026 Sensitive: C3 – Early Trials S95026 Sensitive : C3
EGFR S492R	Colorectal Cancer	EGFR S492R	Colorectal Cancer	S95026 Sensitive: C4 – Case Studies S95026 Sensitive : C4	S95026 Sensitive: C4 – Case Studies S95026 Sensitive : C4
EGFR G465R	Colorectal Cancer	EGFR G465R	Colorectal Cancer	S95026 Sensitive: C4 – Case Studies S95026 Sensitive : C4	S95026 Sensitive: C4 – Case Studies S95026 Sensitive : C4